scholarly journals Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma

2017 ◽  
Vol 105 (4) ◽  
pp. 426-434 ◽  
Author(s):  
Toshiaki Tanaka ◽  
Manabu Kaneko ◽  
Hiroaki Nozawa ◽  
Shigenobu Emoto ◽  
Koji Murono ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Therapeutic Strategy ◽  
Target Lesion ◽  
High Recurrence Rate ◽  
Sunitinib Malate ◽  
Mixed Adenoneuroendocrine Carcinoma ◽  
Regional Lymphadenectomy ◽  
Aggressive Tumor ◽  
Molecular Targeting Agent ◽  
Pathological Confirmation

Colorectal mixed adenoneuroendocrine carcinoma (MANEC), which acts like an aggressive tumor, is a rare clinical manifestation on which only a limited amount of literature exists. Surgical resection by regional lymphadenectomy is considered as the only curative treatment for colorectal MANEC, and adjuvant chemotherapy or radiotherapy is recommended because of its high recurrence rate. Colorectal MANEC is frequently diagnosed at an advanced stage, when it is unresectable, and chemotherapy plays a central role in its treatment. Pathological confirmation of the target lesion component is critical for regimen selection. If the lesion comprises an adenocarcinomatous component, a regimen for colorectal adenocarcinoma should be administered. For lesions comprising mainly a neuroendocrine carcinomatous component, cisplatin combined with etoposide or irinotecan has proven to be clinically appropriate. Everolimus, a mechanistic target of rapamycin pathway inhibitor, also improves survival. Sunitinib malate, another molecular targeting agent, is effective for treating neuroendocrine carcinoma; however, the evidence on its effectiveness for treating gastrointestinal neuroendocrine carcinoma is insufficient.

scholarly journals Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus

Folia Medica ◽  
2020 ◽  
Vol 62 (2) ◽  
pp. 412-417
Author(s):  
Spasimir T. Shopov ◽  
Benyamin L. Anavi ◽  
Dobrin K. Krastev
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Chromogranin A ◽  
Clinical Signs ◽  
Large Cell ◽  
Small Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Morphological Evidence ◽  
Treatment Type ◽  
Aggressive Tumor ◽  
Uterine Body

Large-cell neuroendocrine carcinoma of the endometrium is an insufficiently researched aggressive tumor with a short survival regard­less of the treatment type. We present here the 38th consecutive case of literature reported cases of large cell neuroendocrine carcinoma of the endometrium (posi­tive for synaptophysin, CD56, chromogranin A, p53, and Vimentin) found in the myomatous uterus of a 76-year-old woman. We also describe in the study the morphological algorithm for differentiation of malignant blastomas with small (under 10 %) neuro-endocrinal component. Accumulated clinical and morphological evidence raises the question whether the large-cell and the small-cell neuroendocrine carcino­mas are just different variations according to their histology and topical occurrence (uterine body/cervix) or they are just independent forms with their respective clinical signs, morphology, treatment, and prognosis.

scholarly journals NEUROENDOCRINE CARCINOMA AS SINONASAL MALIGNANCY

2019 ◽  
Vol VOLUME 7 (VOLUME 7 NUMBER 2 NOV 2018) ◽  
pp. 30-34
Author(s):  
Nitya Singh
Keyword(s):  
Nasal Cavity ◽  
Neuroendocrine Carcinoma ◽  
Histopathological Examination ◽  
Neuroendocrine Differentiation ◽  
Imaging Study ◽  
High Recurrence Rate ◽  
Neuroendocrine Neoplasms ◽  
Left Nasal Cavity ◽  
Intravenous Contrast ◽  
Rare Malignancy

Neuroendocrine neoplasms are defined as epithelial neoplasms with predominant neuroendocrine differentiation. Extremely rare site for neuroendocrine carcinoma are nasal cavity and paranasal sinuses and are aggressive neoplasm with a high recurrence rate and a tendency to metastasize. A 19-year male presented to the department of Otorhinolaryngology with left nasal obstruction, persistent headache for nine months and on and off bleeding from left nasal cavity for 2 months. On examination of the nasal cavity, a gross deviation of nasal septum with a red, friable, gelatinous, polypoidal mass with a tendency to bleed was seen in the left nasal cavity. The patient underwent endoscopic excision of mass under GA. Specimen was sent for histopathological examination which exhibited the properties of Neuro-endocrine carcinoma. Sinonasal NEC is an extremely rare malignancy. CT scan with intravenous contrast is the most effectual early imaging study, additionally MRI will further make a fine description of the tumor extension. Furthermore, Immunohisto-chemistry is an important tool that can be valuable in reaching a diagnosis. There is no clear recommendation regarding the treatment of the sinonasal neuroendocrine carcinoma, but the multimodal approach with proper counselling of patient is favoured and generally accepted.

scholarly journals Carcinosarcoma of the nasopharynx: a case report

2021 ◽  
Vol 7 (9) ◽  
pp. 1531
Author(s):  
Monica Kotu ◽  
Ian Paul Olwoch ◽  
Thabo Kgomo
Keyword(s):  
Complete Loss ◽  
High Recurrence Rate ◽  
High Morbidity ◽  
Rare Entity ◽  
Nasal Blockage ◽  
Recurrent Epistaxis ◽  
Histological Appearance ◽  
History Of ◽  
Clear Guideline ◽  
Aggressive Tumor

<p>Carcinosarcoma is a malignant tumor with a dual histological appearance, a squamous epithelial (sarcomatous), and a mesenchymal component. Carcinosarcomas are characterized by a high recurrence rate, metastatic spread, and high morbidity and mortality. Carcinosarcoma can arise from any squamous epithelial lining but rare in the sino-nasal tract. We are presenting a case of a 19-year-old male with a 3-month history of recurrent epistaxis associated with nasal blockage, anosmia, and bilateral complete loss of vision over a few weeks. Carcinosarcoma of the sino-nasal tract is a rare entity and can mimic any sino-nasal malignancy. The optimal treatment of this disease is controversial and lacks a clear guideline, therefore challenging to the treating oncologists.<strong> </strong>Carcinosarcoma of the head and neck is a rare and aggressive tumor. It poses diagnostic and treatment challenges.</p>

scholarly journals Tumor Neuroendocrino del Ciego: Reporte de Caso

2019 ◽  
Vol 30 (2) ◽  
Author(s):  
Paúl Andrade
Keyword(s):  
Intestinal Obstruction ◽  
Neuroendocrine Tumor ◽  
Male Patient ◽  
Neuroendocrine Carcinoma ◽  
Histopathological Examination ◽  
Primary Anastomosis ◽  
Right Hemicolectomy ◽  
Small Cells ◽  
Aggressive Tumor ◽  
Well Differentiated

Neuroendocrine carcinoma (NEC) of the colon is a rare and very aggressive tumor, generally diagnosticated in an incidental way and during resolution of complications such as perforation or intestinal obstruction. The case of a 58-year-old male patient who was surgically intervened for presenting localized peritonitis pedhora scan to a perforated blind neuroendocrine tumor. Right hemicolectomy whit ganglion D2 resection and ileo – transverse primary anastomosis was performed. Histopathological examination described a well-differentiated neuroendocrine carcinoma of small cells, with no vascular or neuronal infiltration. Now the patient is awaiting chemotherapy without the need for secondary surgical review.

scholarly journals Myeloproliferative masks of multiple myeloma: A review of literature and clinical case reports

2017 ◽  
Vol 89 (1) ◽  
pp. 72-77
Author(s):  
V V Ryzhko ◽  
A E Grachev ◽  
A A Klodzinsky ◽  
T V Ivanova ◽  
M S Sataeva ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Therapeutic Strategy ◽  
Case Reports ◽  
Myeloproliferative Disorders ◽  
Molecular Testing ◽  
Review Of Literature ◽  
First Case ◽  
Aggressive Tumor

Concurrences of multiple myeloma with myeloproliferative diseases or secondary myeloid leukemoid reactions are rather rare. The paper describes 3 cases of multiple myeloma: the first case concurrent with neutrophilic leukocytosis; the second case with secondary erythropoetin-dependent erythrocytosis, and the third case with chronic myeloid leukemia. In such cases, an accurate diagnosis requires molecular testing, besides routine clinical and laboratory studies. The paper discusses therapeutic strategy in cases of a concurrence of 2 competing tumors of the blood system: to treat them simultaneously or the most aggressive tumor now, as well as a relationship between multiple myeloma and chronic myeloid leukemia, other myeloproliferative disorders, and secondary myeloid leukemoid reactions.

Sign in / Sign up

Export Citation Format

Share Document